| 发明名称 |
Combined use of PRAME inhibitors and HDAC inhibitors |
| 摘要 |
The invention relates to the cancer antigen PRAME (PReferentially expressed Antigen in MElanoma) and its use in a method of treatment of a tumour which comprises administering to a subject in need of treatment an effective amount of an inhibitor of PRAME, in combination with a second agent selected from the group of an inhibitor of HDAC (an HDACi) and a retinoid. |
| 申请公布号 |
US8969544(B2) |
申请公布日期 |
2015.03.03 |
| 申请号 |
US201113045284 |
申请日期 |
2011.03.10 |
| 申请人 |
|
发明人 |
Bernards René;Epping Mirjam;Wang Liming |
| 分类号 |
C07H21/04;A61K31/7088;A61K31/16;A61K31/203;A61K45/06;C12N15/113;A61K31/18;A61K48/00 |
主分类号 |
C07H21/04 |
| 代理机构 |
Nixon & Vanderhye P.C. |
代理人 |
Nixon & Vanderhye P.C. |
| 主权项 |
1. An inhibitor of PRAME and a second agent selected from the group of an inhibitor of HDAC (an HDAC) and a retinoid, as combined preparation for simultaneous, separate or sequential use in therapy,
wherein the HDACi is N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide, the inhibitor of PRAME is an sRNA sequence based on a contiguous sequence of 10-30 nucleotides from the cDNA sequence of PRAME or a vector encoding said siRNA, and the therapy is treatment of a cancer expressing PRAME. |
| 地址 |
|
